Innovation Funding Database

Choose Your Area of Innovation:

  • Advanced Materials & Manufacturing

  • Aerospace & Spacetech

  • Agtech & Foodtech

  • Artificial Intelligence & Machines Learning

  • Biotech

  • Cleantech & Climatetech

  • Cybersecurity

  • Defensetech & Dual-Use Tech

  • eXtended Reality

  • Healthtech

  • Medtech

  • Other Tech

  • Quantum & Photonics

  • Robotics & Autonomous Systems

Active, Broad Topic Josiah Wegner Active, Broad Topic Josiah Wegner

ERDC BAA - ARMY

Deadline: Rolling Deadline.

Funding Award Size: Est. $2-$10 Million

Description: Funding for research and development supporting military engineering, environmental science, infrastructure resilience, geospatial systems, computing, materials, energy, and related defense and civil works technologies.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army Corps of Engineers’ Engineer Research and Development Center (ERDC) is issuing a continuously open Broad Agency Announcement to fund basic, applied, and advanced research across a wide range of engineering, environmental, and defense-relevant technology areas. Awards are made on a rolling basis through cooperative agreements, subject to the availability of funds so interested companies should submit as soon as possible.

How much funding would I receive?

ERDC does not specify a standard award size. Individual awards may range from small research efforts to very large, multi-year programs, with an overall program ceiling of $1 billion. Funding levels are determined based on technical scope, relevance, and available funding within the sponsoring ERDC laboratory.

What could I use the funding for?

To be eligible for consideration and possible contract award, the technology or methodology shall be either basic research, applied research, advanced technology development not for a specific system/hardware, or demonstration and validation.


If your technology is novel and fits into one of the following Areas of Interest, you could potentially be funded:

Coastal and Hydraulics Laboratory (CHL)

Geotechnical & Structures Laboratory (CHL)

Environmental Sensing

Contaminated Site Characterization, Assessment & Remediation

Sediment Geochemistry and Biological Effects

Environmental and Water Quality Modeling

Environmental Impact Prediction, Assessment and Management

Environmental Criteria for Stream Channel Alteration Projects

More topics in progress (see solicitation for all topics).

Are there any additional benefits I would receive?

Beyond the direct funding, ERDC awards provide meaningful strategic advantages:

Government Validation and Technical Credibility:
Selection by ERDC signals strong alignment with U.S. Army and national infrastructure priorities, which can materially strengthen your credibility with customers, primes, and investors.

Non-Dilutive Technology Maturation:
Companies can advance core technology without equity dilution, preserving ownership while increasing enterprise value.

Long-Term Government Relationship Building:
ERDC BAAs are often a gateway into follow-on DoD contracts, reimbursable work, and sole-source opportunities.

Increased Visibility Across DoD and Civil Works:
Successful projects frequently expand beyond a single lab, creating exposure across USACE, DoD, and federal infrastructure stakeholders.

What is the timeline to apply and when would I receive funding?

This BAA is continuously open until January 1, 2027, and all submissions initially enter the process as pre-proposals. Pre-proposals may be submitted at any time through the ERDCWERX portal and are limited to five pages, plus a one-page executive summary.

ERDC conducts a preliminary technical review of pre-proposals as they are received. Offerors can expect a response within 60 days of submission, either encouraging submission of a full proposal or advising that the pre-proposal was not favorably reviewed.

If a pre-proposal receives a favorable review, ERDC will issue a formal invitation from the Contracting Office to submit a full proposal. Full proposals then undergo scientific peer review, cost evaluation, and funding availability assessment.

There is no fixed award cycle or batch deadline. Awards may be made at any time following successful evaluation and are subject to availability of funds.

Where does this funding come from?

Funding is provided by the U.S. Army Corps of Engineers (USACE) through its Engineer Research and Development Center (ERDC) and supported DoD research programs.

Who is eligible to apply?

Eligibility is unrestricted, meaning any qualified U.S. or international entity may apply, subject to statutory and regulatory requirements. This includes:

  • For-profit companies

  • Startups and small businesses

  • Universities and nonprofit research organizations

What companies and projects are likely to win?

ERDC evaluates proposals based on:

  • Clear alignment with ERDC mission and stated research areas

  • Strong scientific or technical merit

  • Demonstrated capability of the proposing team

  • Practical relevance to military or civil works challenges

  • Realistic scope and cost relative to expected outcomes

Are there any restrictions I should know about?

  • ERDC may limit awards based on funding availability in specific technical areas

  • Some projects may be subject to export control, security, or publication restrictions

  • Proposals must clearly identify whether research is considered “fundamental”

  • Full proposals must be submitted only through designated laboratory channels, not directly to technical staff

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal under this BAA will likely take 20–40 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 for the Pre-Proposal Submission.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Read More
Active, Broad Topic Josiah Wegner Active, Broad Topic Josiah Wegner

Defense Sciences Office (DSO) Office-wide BAA – DARPA

Deadline: June 2, 2026

Funding Award Size: Est. $2 million

Description: Funding for revolutionary basic or applied research that advances science, devices, or systems for national security applications.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DARPA’s Defense Sciences Office (DSO) is soliciting proposals under its Office-wide Broad Agency Announcement (BAA) to fund revolutionary basic or applied research that enables breakthrough advances in science, devices, or systems for national security applications. Proposals are accepted on a rolling basis through June 2, 2026, and may be submitted as executive summaries, abstracts, or full proposals. This BAA is designed to capture novel, high-risk, high-reward ideas not already addressed by existing DARPA programs.

How much funding would I receive?

DARPA anticipates making multiple awards, but no fixed award size or funding range is specified in the BAA. Award amounts, duration, and structure are determined based on the proposed technical scope, cost realism, and selected award instrument. An accelerated award option is available for select proposals not exceeding $2,000,000, with awards made within approximately 30 days of selection.

What could I use the funding for?

Funding may be used to pursue innovative basic or applied research concepts that enable revolutionary (not evolutionary) advances aligned with DARPA’s mission. Proposals may address, but are not limited to, the following DSO technical thrust areas:

  • Materials, Manufacturing, and Structures - Breaking the tension between performance and efficiency for critical parts, production processes, energetics, superconductors, and propulsion

  • Sensing, Measuring, and Affecting - Developing and leveraging new science to overcome existing barriers limiting the performance and/or practicality of sensing, measurement, and control, to achieve orders of-magnitude improvement in operational capabilities.

  • Math, Computation, and Processing - Enabling quantum, reimagining classical, and developing entirely new forms of computing for enhanced efficiency and new capabilities. Solutions may range from new approaches to hardware (implementation) to representation and computation.

  • Complex, Dynamic, and Intelligent Systems - Creating new scientific capabilities for classes of systems that evolve and adapt and for which traditional reductionist, data-driven, and statistical methods fail. Systems of interest include, but are not limited to, foundations of intelligence, human-AI ecosystems, homeostatic mechanisms, and global systems.

Proposals focused primarily on incremental improvements or manufacturing scale-up are explicitly excluded.

Are there any additional benefits I would receive?

Beyond direct funding, selection under a DARPA DSO BAA provides substantial indirect value:

  • DARPA Validation and Credibility: Being selected signals strong technical merit and alignment with DARPA’s mission to create or prevent technological surprise.

  • Increased Visibility: Awardees gain visibility within the national security R&D ecosystem and among DARPA program managers.

  • Access to DARPA Engagement Pathways: Participation can lead to future invitations to targeted DARPA programs, Disruption Opportunities (DOs), or Advanced Research Concepts (ARCs).

  • Nondilutive De-Risking: Advancing frontier technology with nondilutive capital can materially improve company valuation and future exit outcomes.

What is the timeline to apply and when would I receive funding?

  1. Review Process: Rolling through June 2, 2026

  2. Accelerated Award Option: Awards made within ~30 days of selection for qualifying proposals

Where does this funding come from?

Funding is provided by the Defense Advanced Research Projects Agency (DARPA) within the U.S. Department of Defense, through the Defense Sciences Office (DSO).

Who is eligible to apply?

  1. U.S. and non-U.S. organizations may apply

  2. Small businesses, startups, universities, and large firms are eligible

  3. FFRDCs, UARCs, and Government Entities (including National Labs) are not eligible

  4. Non-U.S. participants must comply with export control, security, and nondisclosure requirements

What companies and projects are likely to win?

DARPA evaluates proposals based on the following criteria:

  • Scientific and technical merit of a novel, feasible, and well-reasoned approach

  • Relevance and contribution to DARPA’s mission and national security impact

  • Clear articulation of technical risk and credible mitigation strategies

  • Strong alignment between scope, cost, and schedule realism

  • Ability to enable revolutionary—not incremental—advances

Are there any restrictions I should know about?

  • Incremental or evolutionary improvements are not of interest

  • Manufacturing scale-up is explicitly excluded

  • Some projects may involve Controlled Unclassified Information (CUI) and require compliance with NIST SP 800-171

  • Projects involving human subjects or animal research must follow DARPA approval procedures

  • DARPA retains discretion to determine whether work is fundamental or non-fundamental research

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $5,000 for the Abstract Submission.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

Emerging Weapons, Munitions Systems, and Soldier Lethality BAA

Deadline: Just Extended to March 17, 2026.

Funding Award Size: Est. $1 to $10 million

Description: This BAA funds new, innovative research concepts that advance the state of the art across the full spectrum of Army armaments, munitions, fire control, autonomy, energetics, advanced materials, soldier lethality, logistics, AI/ML, sensors, and related technologies. Proposed efforts must be scientific studies or experimentation that increase knowledge within the DEVCOM Armaments Center technical community.

Executive Summary:

The U.S. Army’s Emerging Weapons and Munitions Systems & Soldier Lethality BAA invites industry and academia to submit innovative R&D concepts that advance a wide variety of critical armament technologies. The program remains open through March 17, 2026, and white papers may be submitted at any time.

How much funding would I receive?

The BAA does not specify individual award ceilings. Awards may be:

  • Contracts for basic/applied research

  • Other Transactions for Research or Prototypes (including cost-share requirements in some cases)

  • Multi-year efforts, typically up to three years, with incremental funding.

The scope and cost depend entirely on the proposed technical approach and feasibility.

What could I use the funding for?

The U.S. Army Futures Command’s Army Modernization Strategy (AMS) will catapult the U.S. Army forward to meet its enduring responsibility as part of the Joint Force to provide for the defense of the United States, and retain and secure its position by 2035 as the globally dominant land power. The end state is a modernized Army capable of conducting Multi-Domain Operations (MDO) as part of an integrated Joint Force in a single theater. The MDO concept describes how the Army will support the Joint Force in the rapid and continuous integration of all domains of warfare – land, sea, air, space, and cyberspace – to deter and prevail as we compete short of conflict, and fight and win if deterrence fails.

The modernization strategy shifts the top focus to mid-term modernization, while maintaining readiness for current operations. The six Army modernization priorities – long range precision fires, next generation combat vehicles, future vertical lift, network, air and missile defense, and soldier lethality are the pillars of our future success. Additionally, the Army will continue to reform its business processes, shifting from Industrial Age to Information Age approaches.

It is anticipated that many future technology developments will be made in conjunction with the tools of the Information Age. Modeling and Simulation (M&S) is considered as a key tool needed to bring next-generation technology to the warfighter on time, and at minimal costs.

M&S should be incorporated into technology developmental efforts whenever possible. Additionally, it is believed that concepts like the Containerized Software Applications & Orchestration, DevSecOps, Government Cloud Software Factories, Internet of Things (IOT), Artificial Intelligence (AI) and Cyber Security (CS) will play increasingly more prominent roles in many of the technologies that will be developed to provide the battlefield overmatch that we need, and to keep our warfighter safe.

The U.S. Army Armaments Center’s Business Interface Office is looking to identify and develop technologies for the purpose of addressing key elements of the Army’s modernization priorities. Efforts under this BAA should focus on the development and demonstration of technology for current and future generation munitions and armament systems, including Logistics. This shall be accomplished via investigative research efforts in the following general technology areas:

Are there any additional benefits I would receive?

Beyond the direct award, companies benefit from:

Government Validation & Technical Credibility
Being selected by DEVCOM Armaments Center signals that your technology aligns with Army modernization priorities—significantly strengthening credibility with primes, integrators, and investors.

Non-Dilutive Technology Maturation
Awards allow companies to advance high-risk, high-impact technologies with non-dilutive capital, increasing enterprise valuation and accelerating commercialization.

Access to Army Technical Stakeholders
Awardees collaborate with government engineers, program offices, and test facilities—creating opportunities for future transition paths, follow-on funding, and insertion into Army programs of record.

Increased Visibility & Notoriety
Participation in Army-funded R&D often enhances visibility with Congress, DoD stakeholders, and defense industry partners.

Strengthened Exit / Acquisition Potential
Demonstrating government-backed R&D progress increases the likelihood of strategic partnerships or acquisition by major defense primes.

What is the timeline to apply and when would I receive funding?

  • BAA Open Period: Open until Mar 17, 2026.

  • White Papers: May be submitted any time during the open period.

  • Evaluation: Approximately 3 weeks after submission.

  • Proposal Requests: Only if the white paper is rated Promising, though any offeror may voluntarily submit a full proposal.

  • Awards: Rolling, contingent on available funding; multi-month contracting timelines should be expected.

Because the BAA is continuously open, funding timing varies but generally follows white paper evaluation → proposal submission → negotiation → award.

Where does this funding come from?

Funding is provided by the U.S. Army Combat Capabilities Development Command (DEVCOM) Armaments Center, located at Picatinny Arsenal, under federal R&D authority including FAR 6.102(d)(2), 10 U.S.C. 2371/2358 (Other Transactions), and applicable DoD research statutes.

Who is eligible to apply?

All responsible sources may apply, including:

  • Traditional and nontraditional defense contractors

  • Small and large businesses

  • Universities and research institutions

  • Nonprofits

The BAA encourages participation from HBCUs and Minority Institutions.

SAM.gov registration is required prior to award. White papers and proposals must be submitted via email to the contracting POCs.

What companies and projects are likely to win?

Highly competitive proposals will:

  • Directly address one of the 28 detailed technology areas (e.g., advanced materials, energetics, AI/ML, fire control, autonomous munitions, logistics, digital engineering).

  • Provide innovative, non-incremental research concepts

  • Demonstrate feasibility, technical merit, and Army relevance

  • Show strong organizational capability, facilities, and past performance

  • Include clear pathways to future Army integration

Funded efforts typically target high-impact, dual-use, defense-relevant technologies aligned to Army modernization priorities such as long-range precision fires, soldier lethality, next-generation combat systems, and advanced energetics.

Are there any restrictions I should know about?

Key restrictions include:

  • Some OT awards may require cost share (e.g., 50/50 for research TIAs).

  • Classified submissions require prior approval and special handling.

  • Possession of a SECRET facility clearance is recommended for potential future phases (not needed to get started).

How long will it take me to prepare an application?

Typical preparation timelines:

  • White Paper: 2–6 weeks depending on complexity.

  • Full Proposal (if requested): 6–12+ weeks for technical, cost, and contractual documentation.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available to submit a white paper for a flat fee of $4,000.

Fractional support is $300 per hour, with most scout card projects requiring 10-12 hours of work.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

Drone Dominance Program (DDP) – One-Way Attack (OWA) sUAS Procurement

Deadline: The Request for Solutions (RFS) is expected December 17, 2025 with Gauntlet I beginning February 17, 2026 (est.). This is a multi-phase program running through January 2028.

Funding Award Size: $5 Million+

Description: The Department of War’s Drone Dominance Program seeks low-cost, U.S.-made small unmanned aerial systems (sUAS) capable of One-Way Attack (OWA) missions. The program aims to rapidly scale American industrial capacity to produce cheap, attritable, combat-ready drones at volume. Companies compete in Gauntlet field events, and high-scoring systems receive fixed-price production orders.

Executive Summary:

The Department of War’s Drone Dominance Program (DDP) will award up to $1 billion in fixed-price orders for companies that can design and manufacture low-cost, NDAA-compliant, One-Way-Attack sUAS at scale. Up to 25 vendors will be invited to Gauntlet I, with winners receiving production orders of at least 1,000 units. The RFS is expected December 17, 2025, and Gauntlet I begins February 2026.

How much funding would I receive?

Awards are fixed-price production orders—no development funding, no cost reimbursement, and no progress payments. Vendors are paid only for accepted units delivered. Planned procurement (page 1 table):

  • 30,000 units in Phase I ($150M total)

  • 60,000 units in Phase II ($300M total)

  • 100,000 units in Phase III ($300M total)

  • 150,000 units in Phase IV ($345M total)

Up to 12 vendors in Phase I will receive orders, with minimum buys of 1,000 units per vendor. Larger orders go to top performers.

What could I use the funding for?

Funding is strictly for production and delivery of compliant, mission-ready low-cost, NDAA-compliant, One-Way-Attack sUAS.

Are there any additional benefits I would receive?

Beyond the production revenue, awardees stand to gain substantial strategic advantages:

Government Validation & Competitive Differentiation
Being selected through Gauntlet scoring—publicly posted via leaderboard—serves as strong validation of performance, reliability, and manufacturing scale. This credibility improves trust with primes, integrators, and future government buyers.

Accelerated Market Visibility
Winners enter widely publicized Gauntlet announcements and procurement cycles. The DoW expects increasing visibility across phases as the program scales toward 200,000+ drones purchased by 2027.

Commercial & Dual-Use Positioning
A proven low-cost, high-reliability sUAS platform creates runway for commercial security, inspection, and tactical robotics markets.

Stronger Exit and Investment Potential
Demonstrating performance at scale via nondilutive production orders increases valuation, derisks manufacturing capability, and strengthens attractiveness for acquisition by defense primes, autonomy companies, and major drone manufacturers.

What is the timeline to apply and when would I receive funding?

  • RFS Release: ~December 17, 2025

  • Selections Notified: Week of January 26, 2026

  • Gauntlet I: Begins February 17, 2026 (est.)

  • Deliveries: Two tranches each phase, due 2.5 and 4.5 months after Gauntlet

Production payments occur upon delivery and acceptance of units.

Where does this funding come from?

The Department of War will issue orders using 10 U.S.C. 4022 Other Transaction Authority, executed through the S2MARTS OTA consortium. The program intends to place up to $1B in fixed-price orders over four phases.

Who is eligible to apply?

Per the program FAQ and RFI:

  • Eligible: Companies from the United States and allied Five Eyes nations

  • Strong Preference: U.S. companies manufacturing in the U.S. with American-made components and materials

  • Systems must be NDAA-compliant (no covered foreign components).

What companies and projects are likely to win?

Winners will be companies that can deliver:

  • Low-cost, attritable sUAS that meet OWA mission requirements

  • 10 km strike range (open terrain) & 1 km (urban) with 2kg payload

  • High reliability and ease of use, with only ~2 hours of operator training needed

  • NDAA-compliant supply chains

  • Production scaling capability into tens of thousands of units per phase

  • Fast delivery under tight 2.5–4.5 month timelines

  • Supply-chain secure manufacturing beyond minimum NDAA rules

Systems must withstand increasingly complex Counter-UAS environments in later phases.

Are there any restrictions I should know about?

Yes:

  • No progress payments; no cost reimbursement—vendors carry all development risk

  • No classified submissions

  • NDAA compliance required

  • Foreign components from covered countries are prohibited

  • All submissions must be made through the NSTXL standardized form

  • Vendors must meet requirements of 10 USC 4022(d)

  • Vendors are limited to fixed-price production only—no R&D funding

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive proposal will likely take 50-100 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee + success fee (Pricing available upon request).

Fractional support is $300 per hour, with most scout card projects requiring 10-12 hours of work.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See RFI on Sam.Gov

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

Army Medical Operational Capabilities for 2040 BAA

Deadline: Rolling Deadline Until 12/31/2030

Funding Award Size: Est. $2 to $5 million

Description: The U.S. Army Medical Capability Development Integration Directorate (MED CDID) is seeking innovative concepts, technologies, and solutions that enable tactical-level Army medical units (Corps and below) to clear the battlefield, maximize return to duty, and overcome contested medical logistics in the 2040 Future Operational Environment. Solutions may address evacuation, prolonged care, diagnostics, advanced therapeutics, predictive and autonomous logistics, and cross-cutting enablers like AI/ML, human-machine teaming, and medical modeling and simulation

Executive Summary:

The MED CDID Broad Agency Announcement (BAA) invites industry and other performers to propose innovative medical concepts and technologies that support tactical Army medical units in the 2040 Future Operational Environment. The program is open through December 31, 2030, using a multi-step process: submission of a Vulcan Scout Card, followed—if selected for further interest—by a white paper and then a full technical and cost proposal. Companies should plan their internal timelines to first shape a high-impact Scout Card aligned to MED CDID’s three imperatives: clearing the battlefield, maximizing return to duty, and overcoming contested logistics.

How much funding would I receive?

The MED CDID BAA does not specify individual award ceilings or a total program funding limit. Instead, offerors must propose a Rough Order of Magnitude (ROM) total cost (including any fee) that is consistent with the scope of work, period of performance, and any dollar ranges specified in the announcement or follow-on calls. Common costs range from $500K to $5M.

What could I use the funding for?

Proposals should address at least one problem associated with the following aspects of the future operational environment (FOE):


a. Enemy action (through fires, maneuver, electronic warfare, etc.) will inhibit evacuation and medical resupply operations. Slow, reduced, or ineffective evacuation or medical resupply delays the Soldier’s treatment at the proper medical treatment facility. When evacuation slows, the consumption of medical treatment items increases, thus compounding the resupply problem. The cumulative effects of inadequate evacuation and medical resupply will reduce the return to duty rate and increase the number of preventable deaths.

b. The proliferation of drones, sensors, and other advanced technologies has made the modern battlefield more transparent than ever before. This transparency, coupled with long range precision and massed fires, requires Army forces to be distributed across a wider area and to displace frequently. Enemy precision and massed fires will result in more frequent mass casualty incidents, which will likely occur in support areas rather than near the front lines. Future medical forces must therefore be highly mobile to conduct survivability moves, to support widely distributed units, and to respond quickly to the point of need with both medical personnel and supplies (Class VIII).

c. The future battlefield will likely have a broad range of man-made and naturally occurring chemical and biological threats. These threats may be varied and difficult to detect and prevent, making early warning systems crucial. Toxic industrial chemicals and toxic industrial materials in urban areas pose additional threats. Directed energy and other new weapons may cause novel wound patterns that require new training and treatments.

d. When operating in urban areas, challenges include moving through routes blocked by rubble, craters, and other obstacles. Medical units must plan to extract patients from collapsed buildings, interaction with civil medical infrastructure, and potentially large numbers of injured civilians and enemy prisoners.

e. An increasingly transparent and lethal battlefield with chem-bio threats and new weapons systems will create continuous physiological and psychological stressors. These stressors will lead to a decline in the cognitive, physical, and emotional aspects of Soldier performance, and thus a decline in unit combat effectiveness. Army medical units must expand capacity to build and restore individual resiliency, to reduce disease non-battle injury (DNBI) losses, and increase return to duty (RTD).

AREAS OF INTEREST

The Army is looking for solutions in the following categories. Please note that these categories are not comprehensive, but rather to provide context. Categories may be created or removed as time progresses:

Are there any additional benefits I would receive?

Beyond the direct award, MED CDID funding offers significant strategic advantages for companies operating in defense, medical technology, logistics, AI/ML, and dual-use innovation:

Government Validation and Credibility:
Being selected by the U.S. Army Medical Capability Development Integration Directorate demonstrates strong technical merit and alignment with Army 2040 operational needs. This validation can accelerate engagement with primes, program offices, integrators, and investors who prioritize government-vetted technologies.

Enhanced Visibility and Notoriety:
Although the BAA does not explicitly promise publicity, MED CDID-aligned innovations often surface in Army medical modernization discussions, technical exchanges, and defense-sector forums—raising your company’s profile across DoD medical, logistics, and capability development communities.

Ecosystem Access and Collaboration Opportunities:
Awardees gain direct interaction with MED CDID, Army Futures Command stakeholders, and operational medical units. These touchpoints can open pathways to experimentation events, requirements discussions, field evaluations, and future contracting opportunities with Army, Joint, and SOF medical acquisition organizations.

Stronger Exit and Acquisition Potential:
Nondilutive DoD funding that advances medical, logistics, or autonomy technologies—combined with Army validation—typically increases a company’s valuation and attractiveness to acquirers in defense, biotech, medtech, autonomy, and advanced manufacturing. Government-backed maturity substantially strengthens both commercial and dual-use exit potential.

What is the timeline to apply and when would I receive funding?

Open period: The announcement is open from its posting date through December 31, 2030, as an open-ended BAA.

  • Submission cadence: Vulcan Scout Cards may be submitted at any time during the open period, subject to the process in the BAA. The government may also issue separate, focused calls for follow-on white papers at any time while the BAA is active.

  • Multi-step process:

    1. Vulcan Scout Card submission.

    2. If of interest, MED CDID may request a white paper and/or

    3. A formal technical and cost proposal.

The BAA does not specify review cycle timing or when funds would be awarded after a proposal is submitted. Actual award timing will depend on when MED CDID issues a request for proposal, internal evaluations, and contracting timelines.

Where does this funding come from?

This opportunity is issued by the U.S. Army Medical Capability Development Integration Directorate (MED CDID), which is responsible for enabling the Army Health System and developing future medical concepts and requirements for the Army and Joint Force

Who is eligible to apply?

The BAA does not restrict eligibility. Typical BAAs accept proposals from:

  • U.S. businesses of any size

  • Universities

  • Nonprofits

  • Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

Based on the BAA’s emphasis, competitive projects are likely to:

  • Directly address one or more of the three MED CDID imperatives:

    • Clearing the battlefield (evacuation, prolonged care, integrated patient-movement C2).

    • Maximizing return to duty (resiliency, OPH, advanced diagnostics and treatment, training).

    • Overcoming contested logistics (advanced manufacturing, predictive MEDLOG, multimodal resupply).

  • Provide innovative, future-oriented solutions for the 2040 operational environment, not just incremental improvements to current practice.

  • Show clear relevance to the described FOE challenges (distributed forces, mass casualties, CBRN threats, urban operations, contested logistics).

  • Leverage cross-cutting enablers such as AI/ML, human-machine teaming, interoperability with joint and allied forces, and medical modeling and simulation to materially improve outcomes (reduced preventable deaths, higher RTD rates, more resilient logistics).

In short, teams that tightly map their concept to these problem statements and demonstrate operational impact for Corps-and-below medical units are best aligned with the BAA.

Are there any restrictions I should know about?

  • Tactical level focus: The BAA is focused on tactical-level (Army Corps and below) medical units, not broader health systems in isolation.

  • Targeted white papers: White papers should address only the specific portion of the BAA the offeror intends to accomplish. Submitting a single white paper that tries to cover the entire scope of the BAA is “most likely” to be rejected.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive scout card under this BAA will likely take 20–30 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available to submit a scout card for a flat fee of $2,500.

Fractional support is $300 per hour, with most scout card projects requiring 10-12 hours of work.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on Vulcan

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

DARPA Information Innovation Office (I2O) Broad Agency Announcement (BAA)

Deadline: Rolling Deadline Until 11/1/26

Funding Award Size: Est. $2 million

Description: DARPA’s Information Innovation Office (I2O) is soliciting revolutionary research in information and computational technologies to provide decisive advantage for U.S. national security. Priority thrusts include: Transformative AI; resilient, adaptable, and secure software and complex systems; offensive and defensive cyber security and privacy; and fighting in the information domain. Proposals must go beyond incremental improvements to current state of the art.

Executive Summary:

DARPA’s Information Innovation Office (I2O) Office-Wide BAA invites proposals for multiple awards to develop revolutionary information and computational technologies in areas such as transformative AI, resilient and secure software, cyber operations, and information-domain capabilities. Abstracts may be submitted on a rolling basis until November 1, 2026, and full proposals until November 30, 2026.

How much funding would I receive?

DARPA does not publish fixed award amounts for this BAA. I2O funds a limited number of proposals, and budgets are determined by the technical approach, the scope of work, and alignment with I2O priorities.

What could I use the funding for?

The Information Innovation Office (I2O) creates groundbreaking science and delivers future capabilities in the information and computational domains to surprise adversaries and maintain enduring advantage for national security. I2O efforts typically address one or more of the following key thrust areas:

Are there any additional benefits I would receive?

Beyond the direct award, DARPA funding offers significant strategic advantages:

Government Validation and Credibility:
Receiving a DARPA award signals exceptional scientific and engineering merit, which accelerates engagement with primes, integrators, strategic partners, and investors.

Enhanced Visibility and Notoriety:
DARPA programs are frequently highlighted in federal communications, technical conferences, and defense media—boosting your company’s profile across the national security sector.

Ecosystem Access and Collaboration Opportunities:
Awardees gain access to DARPA program managers, government labs, test ranges, and a high-level innovation network—opening doors to future contracts and partnerships.

Stronger Exit and Acquisition Potential:
Nondilutive funding that matures breakthrough technology, combined with the DARPA “stamp,” often increases valuation and attractiveness to large defense, aerospace, semiconductor, and AI-focused acquirers.

What is the timeline to apply and when would I receive funding?

Abstracts: May be submitted on a rolling basis until November 1, 2026, at 5:00 p.m. Eastern.

Full proposals: May be submitted on a rolling basis until November 30, 2026, at 5:00 p.m. Eastern.

The BAA does not specify dates for award decisions or when funding would be released; those depend on DARPA’s evaluation and negotiation timelines.

Where does this funding come from?

Funding comes from the U.S. Department of Defense through the Defense Advanced Research Projects Agency (DARPA), specifically the Information Innovation Office (I2O).

Who is eligible to apply?

The BAA does not restrict eligibility. Typical DARPA BAAs accept proposals from:

  • U.S. businesses of any size

  • Universities

  • Nonprofits

  • Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

The evaluation criteria (in descending order of importance) are:

  • Overall Scientific and Technical Merit

    • Innovative, feasible, and complete technical approach.

    • Team expertise and experience aligned with proposed tasks.

    • Clear deliverables and logical task sequence.

    • Identification and credible mitigation of key technical risks.

  • Potential Contribution and Relevance to the DARPA Mission

    • Strengthens the national security technology base.

    • Supports DARPA’s mission to make pivotal early technology investments that create or prevent technological surprise.

  • Plans to Implement Resilient Software (when applicable)

    • Clear capability to design, implement, and deliver resilient software.

    • Ensures interoperability, security, and ability to meet DoD/DARPA mission objectives.

    • Uses formal methods when appropriate to work toward eliminating software vulnerabilities.

  • Cost Realism

    • Costs are realistic and consistent with the technical approach and Statement of Work.

    • Effort leverages relevant prior research to maximize benefit from available funding.

Are there any restrictions I should know about?

  • Abstract requirement: A proposal will not be reviewed unless an abstract has been submitted and DARPA has issued an invitation to propose.

  • Scope of work: Proposers may not propose work that they have already completed or that has already received funding or a positive funding decision from DARPA or another Government agency.

  • Revolutionary advances only: Research that primarily yields evolutionary improvements to existing state of the art is explicitly excluded.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available to submit an abstract for a flat fee of $5,000.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

Applications for Cyber Warfare: Genesis

Deadline: September 29, 2030

Funding Award Size: $10 million to $50 million

Description: Funding to develop cyber operations prototypes that can transition into operational DoD platforms to maintain U.S. superiority in the cyber domain.

Executive Summary:

The Air Force Research Laboratory (AFRL) is offering up to $99.99M per award through the Applications for Cyber Warfare: Genesis ARA to develop advanced cyber operations prototypes for transition to operational DoD platforms. White papers are accepted until September 29, 2030.

How much funding would I receive?

Typical awards range from $10M to $50M, with the possibility of awards up to $99.99M. Projects generally span up to 60 months.

What could I use the funding for?

Technologies of interest to the strategic vision of this ARA include, but are not limited to: platforms and architectures for the facilitation of cyber operations, command and control capabilities for the facilitation of cyber operations, effects based capabilities for the facilitation of cyber operations, predictive analysis capabilities for the facilitation of cyber operations, cross domain capabilities for the facilitation of cyber operations, intelligence gathering capabilities for the facilitation of cyber operations, intelligence processing capabilities for the facilitation of cyber operations, stealth delivery capabilities for the facilitation of cyber operations, stealth and persistence capabilities for the facilitation of cyber operations, and planning based utilities for the facilitation of cyber operations.

Are there any additional benefits I would receive?

Beyond the direct funding, awardees gain several indirect advantages:

Government Validation and Technical Credibility:
Winning an AFRL-funded cyber program signals that your technology meets high national-security thresholds—accelerating trust with primes, operators, and investors.

Enhanced Visibility and Notoriety:
AFRL awardees often receive recognition in government communications and defense-tech media, elevating your company’s profile in the cyber and national-security ecosystem.

Pathway to Follow-On Production:
OT prototype awards may transition to follow-on production contracts, enabling larger-scale procurement without a new competition—significantly increasing commercial value.

Stronger Valuation and Exit Potential:
Scaling cyber technologies under nondilutive funding, coupled with Air Force validation, can improve investor confidence and long-term acquisition potential in the defense tech sector.

What is the timeline to apply and when would I receive funding?

White papers may be submitted anytime before September 29, 2030, but AFRL recommends aligning with fiscal-year funding cycles:

  • FY26: by December 30, 2025

  • FY27: by September 30, 2026

  • FY28: by September 30, 2027

  • FY29: by September 30, 2028

  • FY30: by September 30, 2029

Selected offerors will be invited to submit full proposals. Funding timing depends on fiscal-year availability but typically follows several months after invitation and review.

Where does this funding come from?

Funding comes from the Department of the Air Force, Air Force Materiel Command, through the Air Force Research Laboratory (AFRL), Rome Research Site.

Who is eligible to apply?

Eligible applicants include U.S. organizations capable of conducting advanced research and prototype development. Both FAR-based contracts and Other Transactions (OTs) may be awarded. There is no set-aside, allowing large businesses, small businesses, and research institutions to participate.

What companies and projects are likely to win?

Competitive submissions will:

  • Demonstrate strong capability to develop cyber operations prototypes

  • Present feasible transition paths to DoD operational platforms

  • Show technical merit and alignment with cyber dominance objectives

  • Provide credible teams with relevant cyber R&D and integration experience

Projects focused on scalable, operationally relevant cyber capabilities with clear transition potential are most likely to receive funding.

Are there any restrictions I should know about?

  • Awards may be issued as either FAR-based contracts or Other Transactions (OTs) under 10 USC 4021–4023. Each mechanism has different compliance requirements and follow-on potential, especially for successful prototype efforts .

  • While technical and contracting discussions are allowed, communications with AFRL do not constitute a government commitment to fund or award any proposal. Only Contracting Officers can legally bind the government .

  • Applicants are cautioned that failure to follow proposal formatting or submittal instructions may result in lower evaluation ratings or rejection .

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive white paper will likely take 20–50 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the white paper for $5,000.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Access the funding announcement here.



Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

CIRM CLIN2: Funding Opportunity for Clinical Trials

Deadline: January 30, 2026

Funding Award Size: <$15 Million

Description: CIRM’s CLIN2 program funds the completion of interventional Phase 1, 2, and 3 clinical trials for stem cell–based and genetic therapies targeting serious unmet medical needs. Funding supports clinical operations, manufacturing, regulatory work, patient outreach, mechanism and potency studies, access and affordability planning, and data-sharing infrastructure.

Executive Summary:

CIRM’s CLIN2 program provides up to $15M to advance interventional Phase 1–3 clinical trials for stem cell–based and genetic therapies addressing serious unmet needs. Applications are accepted quarterly, with 2026 deadlines falling on the last business day of January, April, July, and October at 2:00 PM PST.

How much funding would I receive?

Funding depends on the stage of your clinical trial:

  • First-in-Human: Up to $8M (for-profit) / $12M (non-profit)

  • Phase 2/Subsequent Phase 1: Up to $15M

  • Phase 3/Pivotal: Up to $15M

What could I use the funding for?

The CLIN2 award supports completion of an interventional phase 1, 2 or 3 clinical trial for a stem-cell based or genetic therapeutic candidate and may also fund an associated natural-history comparator or lead-in normal healthy volunteer study. Applicants are encouraged to use accelerating trial designs where appropriate, such as basket trials or adaptive design dose-escalation protocols.

The CLIN2 Program aims to advance clinical candidates that have the potential for transformative patient impact and that address barriers to access and affordability. To support this goal, align with Proposition 14’s mandate, and remain responsive to an evolving scientific and regulatory landscape, funding preferences will be set on an annual basis. These preferences will be guided by portfolio analyses and other strategic considerations in a cyclical manner.

For fiscal year 2025-2026 CLIN2 cycles, the following modalities and project features will be prioritized:

  • Pluripotent stem cell-derived therapies

  • In vivo genetic therapies

  • Therapies using non-viral nucleic acid delivery

  • Projects addressing diseases of the brain and CNS

  • Applications from California organizations

  • Projects progressing from CIRM-funded IND-enabling or earlier phase clinical trial awards

  • Projects with Fast Track, RMAT or Breakthrough designations

  • Projects proposing pivotal clinical trials (as agreed-to by the FDA)

Are there any additional benefits I would receive?

Government Validation and Credibility
CIRM’s rigorous review provides a powerful credibility signal to investors, strategic partners, and clinical collaborators.

Enhanced Visibility and Notoriety
Awardees benefit from increased recognition through CIRM communications and visibility across the state’s stem cell and gene therapy ecosystem.

Access to CIRM’s Specialized Infrastructure

  • Alpha Clinics Network for trial acceleration and patient access

  • GMP Manufacturing Network for cell and gene therapy manufacturing

  • Industry Resource Partners including preferred CROs and CDMOs

Stronger Exit and Valuation Potential
Nondilutive capital allows companies to advance high-value programs without dilution, often increasing valuation and improving partnership or acquisition outcomes.

What is the timeline to apply and when would I receive funding?

Applications Accepted: Quarterly

  • 2026 Deadlines: Last business day of January, April, July, October at 2:00 PM PST

  • GWG Scientific Review: ~90 days after deadline

  • Board Approval: ~60 days after review

  • Project Start: Within 60 days of approval

Total time from submission to project kickoff: ~6 months.

Where does this funding come from?

Funding is provided by the California Institute for Regenerative Medicine (CIRM) through Proposition 14, which supports the advancement of stem cell and genetic medicine programs statewide.

Who is eligible to apply?

For-profit or non-profit organizations

  1. FDA-cleared IND (or submitted IND for CIRM-funded programs with clearance within 30 days)

  2. PI with ≥15% effort

  3. Project Manager with ≥50% effort

  4. Data Project Manager

  5. Applicant must be the IND sponsor

  6. At least one California trial site

  7. Must begin work within 60 days of board approval

  8. Must meet co-funding and solvency requirements

What companies and projects are likely to win?

CIRM scores applications across five scientific merit categories:

1. Value Proposition – Whether the therapy offers meaningful clinical improvement over existing options, addresses unmet need, and is practical for real-world uptake by patients, providers, and payors.

2. Scientific Rationale – Strength of the biological justification, robustness of supporting data, and evidence of disease-modifying activity from relevant models or prior clinical studies.

3. Project Plan & Design – Whether proposed activities efficiently advance development, enable clear go/no-go decisions, support timely enrollment, include appropriate manufacturing plans, and can be delivered within the proposed budget, timeline, and risk-mitigation strategy.

4. Team & Resources – Expertise and coordination of the project team, access to required facilities (including manufacturing), and track record with stem cell or gene therapy programs.

5. Population Impact – Understanding of the affected population and strength of plans for representative outreach, enrollment, and retention.

Are there any restrictions I should know about?

No funding for discovery or early translational research:

  1. No pre-approval costs

  2. No out-of-state work where the external organization retains IP/publication rights

  3. Co-funding required for for-profits (30–50%)

  4. Only one CLIN2 application per PI per cycle

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive proposal will likely take 150–250 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for $15000 Initial Fee + a 3% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement Here.



Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development

Deadline: July 31, 2028

Funding Award Size: $2 Million to $10 Million

Description: Funding for research and development that advances biomedical solutions, human performance optimization, and medical readiness technologies supporting U.S. Special Operations Forces. Projects may address areas such as damage control resuscitation, prolonged field care, medical sensors and diagnostics, brain health, force protection, canine medicine, or other SOF-relevant capabilities.

Executive Summary:

United States Special Operations Command (USSOCOM) is awarding $2,000,000 to $10,000,000 for projects across defined Research Areas of Interest (RAIs) to advance biomedical, human performance, and canine medicine relevant to Special Operations Forces. This BAA is open continuously through 31 July 2028; applicants must first submit a pre-proposal via eBRAP and, if invited, a full application (generally within 60 days of invitation).

How much funding would I receive?

  1. Typical project size: $2 Million to $10 Million

  2. Program capacity: “Anticipated total costs… will not exceed $20 Million annually” across all awards funded under this BAA.

What could I use the funding for?

A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) to support far-forward early intervention of life-threatening illnesses or injuries within an Irregular Warfare or asymmetric, multi-domain operational environment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be simple to employ, require minimum maintenance, and have low power consumption. Drugs and biologics should optimally not require refrigeration or other special handling. All materiel solutions must be capable of commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements. The proposed research must be relevant to active-duty service members, veterans, military beneficiaries, and/or the American public. Relevant research must be responsive to the health care needs of the U.S. Armed Forces, family members of the U. S. Armed Forces, and U.S. Veterans.

Proposals must address a relevant health problem responsive to one of the Research Areas of Interest below (Clinical trials are normally not funded by this BAA):

Are there any additional benefits I would receive?

Beyond direct funding, participation under the USSOCOM Biomedical and Human Performance BAA offers significant strategic advantages:

Government Validation and Credibility:
Being selected for funding by USSOCOM demonstrates exceptional technical capability and mission relevance to U.S. Special Operations Forces. This validation enhances your organization’s credibility with DoD program managers, defense primes, and dual-use technology investors seeking field-proven innovation.

Enhanced Market Visibility and Notoriety:
Awardees often gain visibility through federal award announcements, DoD communications, and defense medical research forums—positioning your company as a recognized contributor to national security and elite force readiness.

Ecosystem Access and Collaboration Opportunities:
Projects funded under this BAA operate within the broader military biomedical and human performance ecosystem, connecting recipients with military laboratories, medical R&D commands, and operational units. This access frequently leads to additional collaboration, follow-on funding, and contracting opportunities.

Stronger Exit and Acquisition Potential:
Advancing your technology with nondilutive government support and demonstrating validation in demanding SOF environments can significantly increase company valuation and strategic attractiveness for acquisition or investment by defense, medical, and performance technology leaders.

What is the timeline to apply and when would I receive funding?

  • Open period: Continuously open through 31 July 2028.

  • Two-step submission: Pre-proposal via eBRAP; if invited, submit the full application (generally within 60 days).

  • Review & notice: Applicants should receive disposition within ~180 days of submission; awards may be made any time throughout the year and are contingent on funding and successful negotiations.

  • Regulatory lead times: Allow 2–3 months for DoD human-subjects review (OHRO/HRPO) and 1–2 months for animal research review (VRO), as applicable.

Where does this funding come from?

Funding is provided by the Department of Defense (USSOCOM) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA); the program leverages CDMRP/eBRAP systems. Any funds received by USSOCOM appropriate to the BAA’s research areas may be used, up to a program total of $20M annually.

Who is eligible to apply?

Organizations only: national/international, for-profit, non-profit, public, and private. FFRDCs are not eligible for direct awards but may team under their sponsoring agreements. Eligible investigators are individuals employed by/affiliated with eligible organizations. No cost sharing is required.

What companies and projects are likely to win?

Winning projects consistently score high on USSOCOM’s evaluation factors, which include:

  • Technical Merit and Scientific Rigor: The proposed approach must be well-founded, methodologically sound, and clearly linked to measurable outcomes.

  • Innovation and Impact: Reviewers favor projects that introduce novel methods, materials, or technologies capable of significantly improving SOF medical or performance capabilities. Incremental improvements without clear operational relevance tend to score poorly.

  • SOF Relevance: Proposals must explicitly tie their work to unique SOF operational needs—such as portability, durability, limited logistics support, or extreme-environment applicability.

  • Feasible Study Design and Realistic Execution Plan: Reviewers expect achievable milestones, well-defined deliverables, and credible transition pathways for eventual use by operational forces or integration into DoD systems.

  • Qualified Team and Institutional Capability: Teams with demonstrated expertise in biomedical R&D, human performance, or defense health technology—and with access to appropriate facilities and regulatory infrastructure—are prioritized.

  • Appropriate and Realistic Budget: Budgets should align with the scope and complexity of work, typically falling between $2 million and $10 million total costs for projects up to five years in duration.

Companies that combine strong technical innovation, credible execution capability, and a direct line of sight to SOF mission impact are most likely to be selected for funding.

Are there any restrictions I should know about?

  • Project length: Up to 5 years.

  • Pre-proposal required; unsolicited full proposals without invitation are rejected.

  • Clinical trials are typically not associated with this BAA.

  • Human/animal research approvals required.

  • Administrative pitfalls leading to rejection/withdrawal include: missing/over-limit narratives, missing budget, inclusion of URLs in prohibited sections, and inconsistencies between pre-proposal and full application.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the pre-proposal for $7000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement: HT9425-23-S-SOC1 BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense



Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

ARPA-H Scalable Solutions Office (SSO) BAA

Deadline: Rolling basis until March 5, 2029.

Funding Award Size: Typically varies by project scope; proposers should request only what is necessary to reach a meaningful technical milestone—often $2 million or more for high-impact efforts.

Description: Funding for revolutionary solutions that expand equitable access, affordability, and rapid deployment of health innovations across the U.S. healthcare landscape. The SSO ISO supports scalable technologies that enhance distribution, biomanufacturing, and delivery systems to reach every patient efficiently and affordably.

Executive Summary:

ARPA-H’s Scalable Solutions Office (SSO) has an open “Mission Office Innovative Solutions Opening (ISO)” to fund revolutionary solutions that expand access, affordability, manufacturing, and distribution of health technologies across the U.S. healthcare system. The ISO accepts Solution Summaries and, if encouraged, full proposals; it anticipates multiple awards made as Other Transactions (OTs). The solicitation is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions Office (SSO). The SSO seeks to improve health care access and affordability through revolutionary technical innovations that address the challenges of geography, distribution, manufacturing, and data- and information management. Many communities and remote areas in the United States lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.

Funded SSO health innovation projects will improve the readiness of technologies and medical capabilities to be rapidly, broadly, and affordably adopted by patients, providers, and payers throughout the healthcare ecosystem and improve the patient experience. Manufacturing and supply chain focused SSO projects will lower the bar to entry for new developers, accelerate the rate of development, reduce development and product costs, and improve reliability and agility in manufacturing and product distribution.

Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Scalable Solutions Office (SSO) agreement:

  • Government Validation and Credibility:
    Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

  • Ecosystem Access and Collaboration Opportunities:
    ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

  • Nondilutive Growth and Strategic Leverage:
    Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

  • Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

  • Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

  • Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

  • Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

  1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

  2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

  3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

  4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

  • Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

  • Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

ARPA-H Resilient Systems Office (RSO) BAA

Deadline: Rolling basis until March 5, 2029.

Funding Award Size: Typically varies by project scope; proposers should request only what is necessary to reach a meaningful technical milestone—often $2 million or more for high-impact efforts.

Description: Funding for transformative health system innovations that strengthen the resilience, adaptability, and interoperability of U.S. healthcare. The RSO ISO supports breakthrough solutions that enhance system robustness, improve efficiency, and safeguard access to care during disruptions.

Executive Summary:

ARPA-H’s Resilient Systems Office (RSO) is accepting innovative Solution Summaries and full proposals—on a rolling basis—aimed at strengthening the adaptability, reliability, and interoperability of the U.S. health ecosystem. Multiple awards are anticipated under flexible Other Transaction (OT) agreements. The ISO is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Resilient Systems Office (RSO), one of ARPA-H’s mission offices, seeks project proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. Submissions should aim for groundbreaking ideas that solve systemic challenges across the health landscape, leveraging cutting-edge technologies that address long-standing gaps in the quality, consistency, personalization, and efficacy of care.

RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. While RSO welcomes “out of the box” ideas to address the above gaps, the mission office encourages proposals that address the following areas:

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Resilient Systems Office (RSO) agreement:

  • Government Validation and Credibility:
    Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

  • Ecosystem Access and Collaboration Opportunities:
    ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

  • Nondilutive Growth and Strategic Leverage:
    Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

  • Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

  • Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

  • Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

  • Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

  1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

  2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

  3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

  4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

  • Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

  • Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

ARPA-H Proactive Health Office (PHO) BAA

Deadline: Rolling basis until March 5, 2029.

Funding Award Size: Typically varies by project scope; proposers should request only what is necessary to reach a meaningful technical milestone—often $2 million or more for high-impact efforts.

Description: Funding for transformative, prevention-focused innovations that extend health span and avert disease before it occurs. The PHO ISO supports bold solutions in early detection, behavior change, and system-level redesign to build a proactive, resilient, and equitable health future.

Executive Summary:

ARPA-H’s Proactive Health Office (PHO) has an open Innovative Solutions Opening (ISO) to fund high-impact R&D that improves health span and health outcomes before disease onset. The ISO accepts Solution Summaries now through March 5, 2029, with multiple awards anticipated under Other Transactions (OTs). Eligible proposers include for-profit companies, non-profits, and academia. Solutions must be novel (not incremental) and align with PHO interests in prevention, early detection, behavior change, and system-level innovations.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Proactive Health Office (PHO), one of ARPA-H’s mission offices, is seeking solutions to improve the health spans and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that: 1) the development of novel early detection methods and prophylactic interventions could drastically improve the health of American throughout their lives; 2) population-level improvements in access to and uptake of disease increase prevention- and wellness-promoting behaviors; and 3) system-level innovations are required to deliver proactive health measures effectively.

Specific PHO interest areas include:

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Proactive Health Office (PHO) agreement:

  • Government Validation and Credibility:
    Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

  • Ecosystem Access and Collaboration Opportunities:
    ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

  • Nondilutive Growth and Strategic Leverage:
    Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

  • Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

  • Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

  • Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

  • Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

  1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

  2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

  3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

  4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

  • Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

  • Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Read More
Broad Topic, Active Josiah Wegner Broad Topic, Active Josiah Wegner

ARPA-H Health Science Futures (HSF) Mission Office BAA

Deadline: Rolling basis until March 5, 2029.

Funding Award Size: Typically varies by project scope; proposers should request only what is necessary to reach a meaningful technical milestone—often $2 million or more for high-impact efforts.

Description: Funding for revolutionary, disease-agnostic health innovations that remove scientific and technological barriers to next-generation healthcare. The HSF ISO supports cutting-edge tools, technologies, and platforms with the potential for real-world translational impact.

Executive Summary:

The ARPA-H Health Science Futures (HSF) Mission Office is accepting Solution Summaries and full proposals for revolutionary health R&D under its Innovative Solutions Opening (ISO), ARPA-H-SOL-24-104. Multiple awards are anticipated via Other Transaction (OT) agreements. The ISO remains open through March 5, 2029, and you must submit a short Solution Summary and receive written feedback before a full proposal. Submissions must align with HSF focus areas (e.g., breakthrough technologies, transformative tools, and adaptable platform systems) and are expected to be high-risk, high-impact—incremental or clinical-trial-stage efforts are out of scope.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. The HSF mission office expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. The HSF mission office
supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change. Specifically excluded from consideration are proposals that represent an evolutionary or incremental advance in the current state of the art, or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed toward policy changes; traditional education and training; center coordination, formation, or development; and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The following areas define the ground-breaking research that HSF seeks to support:

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Health Science Futures (HSF) agreement:

  • Government Validation and Credibility:
    Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

  • Ecosystem Access and Collaboration Opportunities:
    ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

  • Nondilutive Growth and Strategic Leverage:
    Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

  • Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

  • Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

  • Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

  • Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

  1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

  2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

  3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

  4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

  • Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

  • Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

Continuing Enabling, Enhancing, Restoring and Sustaining (CHEERS) Multiple Authority Announcement (MAA)

Deadline: September 30, 2027

Funding Award Size: $300K to $5 Million+

Description: : Funding for advancing technologies that enhance human performance, resilience, and health in aerospace and defense environments.

Executive Summary:

The Air Force Research Laboratory’s Human Effectiveness Directorate (AFRL/RH) and the U.S. Air Force School of Aerospace Medicine (USAFSAM) are awarding up to $1 billion in total funding under the CHEERS Multiple Authority Announcement (MAA) to support U.S. companies, universities, and research partners advancing technologies that enhance human performance, resilience, and health in aerospace and defense environments.

White papers are accepted through September 30, 2027, and proposal invitations are issued on a rolling basis. Companies should submit white papers as soon as possible in order to have the highest likelihood of funding.

How much funding would I receive?

Funding is project-dependent and determined by the technical approach propose. Typical awards will range from $300,000 to $5,000,000.

What could I use the funding for?

Funding can used for the full range of R&D activities from basic and applied R&D to prototype and experimental testing. See a list of focus areas below:

Are there any additional benefits I would receive?

Beyond direct funding, CHEERS participation offers significant indirect advantages for growth and strategic positioning:

Government Validation and Credibility:
Selection under AFRL’s CHEERS program signals strong technical merit and alignment with Department of the Air Force human performance priorities—an endorsement that enhances your credibility with defense primes, OEMs, and investors.

Enhanced Market Visibility and Notoriety:
Awardees benefit from exposure in federal announcements, AFRL communications, and defense industry press—raising visibility and positioning your company as a trusted innovation partner in the human-performance and aerospace ecosystem.

Ecosystem Access and Collaboration Opportunities:
CHEERS projects operate within a national network that includes top-tier military researchers, AFRL directorates, and medical readiness centers. This access often leads to future R&D partnerships and contracting opportunities.

Stronger Exit and Acquisition Potential:
By advancing your technology with nondilutive support and demonstrating government-backed validation, companies can increase valuation and strengthen their position for acquisition or strategic investment by defense and medical technology leaders.

What is the timeline to apply and when would I receive funding?

  • White Paper Deadline: Rolling through September 30, 2027. This means applicants should apply as soon as possible before funds are fully expended.

  • Review Period: Technically 180 days for AFRL to review white papers - but it could also be reviewed faster.

  • Proposal Invitation: AFRL will invite full proposals only from offerors whose white papers align with Air Force needs.

  • Proposal Deadline: Defined in each Request for Proposal (RFP).

  • Award Timing: Awards are issued once funds become available; no awards are made until funding is confirmed.

Where does this funding come from?

Funding is issued by the Air Force Research Laboratory (AFRL) under the following authorities:

  • Open Period 1: 10 U.S.C. 4001 / FAR 35.016 (Broad Agency Announcement).

  • Open Period 2: 10 U.S.C. 4023 (Procurement for Experimental Purposes).

These authorities allow AFRL to fund both research contracts and prototype agreements, depending on project maturity and experimental needs.

Who is eligible to apply?

  1. Open to U.S. companies, universities, and research organizations.

  2. Foreign participation is allowed subject to export and security controls.

  3. Cost sharing is not required.

  4. Offerors may submit multiple white papers, provided each represents a distinct technical approach.

What companies and projects are likely to win?

Offer innovative, defense-relevant solutions that measurably enhance warfighter performance, medical readiness, or operational resilience.

  1. Demonstrate clear technical feasibility, transition potential, and sound risk mitigation.

  2. Show strong alignment with AFRL’s human effectiveness and medical research priorities.

  3. Have experienced teams capable of performing under experimental or prototype authorities.

Evaluation criteria (in descending order of importance):

  1. Uniqueness and innovation.

  2. Understanding of scope and technical approach.

  3. Technical soundness and team qualifications.

  4. Transition potential.

  5. Cost realism and value.

Are there any restrictions I should know about?

  • Export Control: Some projects may require U.S. or Canada Joint Certification (DD 2345).

  • Human/Animal Subjects & Hazardous Materials: Approval requirements vary by project and will be outlined in each solicitation.

  • S&T Protection: AFRL’s Science and Technology protection and OPSEC rules apply.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive white paper + full proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the White Paper for $3000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcements:



Read More
Broad Topic, Active Josiah Wegner Broad Topic, Active Josiah Wegner

CHIPS Research & Development Office (CRDO) Broad Agency Announcement

Deadline: Rolling Basis - Apply ASAP before funds are gone.

Funding Award Size: $10 Million or more.

Description: Funding for research, prototyping, and commercialization projects that advance U.S. microelectronics, including work tied to AI, quantum, biotechnology/biomanufacturing, commercialization of innovation, and standards.

Executive Summary:

The CHIPS Research and Development Office (CRDO) at NIST is awarding at least $10 Million per award—via Other Transaction (OT) agreements—for research, prototyping, and commercialization projects that advance U.S. microelectronics, including work tied to AI, quantum, biotechnology/biomanufacturing, commercialization of innovation, and standards. Applications are accepted on a rolling basis which means companies should submit white papers ASAP. Receive a complimentary assessment to see if your company and project is a fit for this funding.

How much funding would I receive?

Budgets should be at least $10 million and reflect actual project needs. CRDO may fund only a portion of total costs and can fund multi-phase projects incrementally based on satisfactory progress, mission fit, and availability of funds. Awards are negotiated as OT agreements. Cost sharing is not required for all awards, though CRDO may choose to fund only part of a project.

What could I use the funding for?

Eligible activities include research, prototyping, and commercialization efforts that strengthen U.S. leadership and the domestic semiconductor ecosystem. Priority topic areas include:

  • Semiconductors (e.g., advanced testing/assembly/packaging, next-gen devices and memory, design co-optimization, automation/AI in fabs, secure supply chains)

  • Application of AI for advanced microelectronics R&D (e.g., compute efficiency, edge AI, cryogenic ops, fab acceleration)

  • Application of quantum technology (e.g., scalable quantum computing, quantum networks/sensing, domestic production of quantum hardware)

  • Application of biotechnology/biomanufacturing for microelectronics (e.g., bioelectronics, implantable devices, scaling domestic bio-electronics manufacturing)

  • Commercialization of innovations (e.g., adopting and commercializing federally funded discoveries, including through consortia)

  • Standards development (e.g., quantum manufacturing, data/design/provenance/security standards).

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving a CHIPS R&D Office (CRDO) award:

  • Government Validation and Credibility:
    Being selected by NIST’s CRDO signals strong technical credibility and alignment with national semiconductor priorities. That stamp of approval often accelerates partnerships with OEMs, primes, and investors who trust government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients frequently receive public recognition in federal announcements, CHIPS R&D Office communications, and industry press. This visibility helps position your company as a trusted, strategic player in the microelectronics ecosystem.

  • Ecosystem Access and Collaboration Opportunities:
    CRDO-funded projects are part of a national innovation network—creating opportunities to collaborate with leading researchers, manufacturers, and other awardees. Such access can unlock supply chain partnerships and future contracting opportunities.

  • Stronger Exit and Acquisition Potential:
    By maturing technology under nondilutive support and demonstrating government-backed validation, recipients often achieve greater value at exit—especially when positioning for acquisition by larger defense, semiconductor, or AI hardware firms.

What is the timeline to apply and when would I receive funding?

Applications (beginning with a required White Paper) are accepted on a rolling basis through September 30, 2029 via Grants.gov. If a White Paper shows sufficient merit and relevance, CRDO may invite a Pre-negotiation Package (detailed technical and cost proposal). Awards are made on a rolling basis as packages are evaluated and terms are finalized. A specific funding disbursement date is not specified. Maximum project period is up to 5 years.

Where does this funding come from?

U.S. Department of Commerce, NIST—through the CHIPS Research and Development Office (CRDO)—under authority including 15 U.S.C. § 4656 and related CHIPS R&D statutes/policies. Assistance Listing: 11.042 CHIPS R&D.

Who is eligible to apply?

Domestic entities only: for-profit organizations, non-profits, accredited higher-education institutions, FFRDCs, and Federal entities (with conditions). Individuals and unincorporated sole proprietors are not eligible. Subawardees may include the above and foreign partners not otherwise prohibited, subject to security and other requirements.

What companies and projects are likely to win?

Projects that:

  • Advance national and economic security and U.S. technology leadership by strengthening domestic semiconductor supply chains and workforce

  • Demonstrate strong scientific/technical merit with clear deliverables

  • Show feasibility (experienced team, realistic costs, risk mitigation)

  • Have credible commercial viability (market demand, transition plan)

  • Show financial viability (sound capex, financial health, credible capital plan).

Are there any restrictions I should know about?

  • Domestic production and control of IP: Foreign entities can apply but should develop and own the IP in the US.

  • Security restrictions: no funds to foreign entities of concern; compliance with research security disclosures; prohibition on malign foreign talent recruitment programs

  • CRDO may require return-on-investment instruments (e.g., equity, warrants, IP licenses, royalties/revenue sharing)

  • Scope: general AI projects not directly tied to advanced microelectronics R&D are out of scope

  • Reporting: financial, performance, and/or technical reports are required.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–180 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under CHIPS R&D initiatives.

How much would BW&CO Charge?

Our support is available at $300 per hour, with most CRDO proposal projects requiring 80–100 hours of expert support from strategy through submission.

For non-VC backed startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.



Read More
Broad Topic Josiah Wegner Broad Topic Josiah Wegner

DARPA Biological Technologies Office (BTO) Broad Agency Announcement

Deadline: September 30, 2026.

Funding Award Size: $2 million+

Description: Funding for transformative biology-enabled capabilities for national security.

Executive Summary:

DARPA’s Biological Technologies Office (BTO) is accepting rolling proposals to fund transformative biology-enabled capabilities for national security. An abstract is required before a full proposal, and both abstracts and proposals are accepted until September 30, 2026. For selected proposals ≤$2,000,000 that opt into the accelerated path, awards can be made within 30 days of selection. Companies targeting this BAA should submit an abstract as soon as possible as they are reviewed on a rolling basis.

How much funding would I receive?

Funding levels are not pre-set; BTO anticipates multiple awards across topics. An optional accelerated award path is available for selected proposals not exceeding $2,000,000 total, using model agreements tailored for small and large businesses.

What could I use the funding for?

Research & Development proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

Are there any additional benefits I would receive?

Beyond the formal award, there are significant indirect benefits to receiving a DARPA Biological Technologies Office (BTO) contract or agreement:

  • Government Validation and Credibility:
    Being selected by DARPA—the Department of Defense’s premier innovation agency—signals extraordinary technical credibility and alignment with national security priorities. This “DARPA validation” often accelerates partnerships with primes, OEMs, and investors who trust government-vetted innovation.

  • Enhanced Market Visibility and Notoriety:
    Award recipients frequently receive public recognition through DARPA announcements, defense innovation conferences, and press coverage. This visibility helps position your company as a cutting-edge player in defense biotech and deeptech, attracting further investment and talent.

  • Ecosystem Access and Collaboration Opportunities:
    DARPA performers gain access to the BTO’s extensive network, including technical advisors, transition partners, and resources. These programs support contractor readiness, compliance, and downstream transition—opening doors to additional government and industry contracts.

  • Nondilutive Growth and Strategic Leverage:
    Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

  • Faster Execution and Credible Track Record:
    With DARPA’s accelerated contracting path, companies can move from selection to award in as little as 30 days—establishing a record of execution under one of the most selective R&D programs in the world, which strengthens competitiveness for future federal or dual-use opportunities.

What is the timeline to apply and when would I receive funding?

Abstracts are accepted on a rolling basis until September 30, 2026, 4:00 PM ET (abstract and DARPA invitation are required before any full proposal).

Full proposals are accepted on a rolling basis until September 30, 2026, 4:00 PM ET.

Accelerated option (≤$2M) awards may be issued within 30 days of selection notification if you submit the required election/attestations and use the model agreement.

Where does this funding come from?

The Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office

Who is eligible to apply?

All responsible sources—U.S. and non-U.S.—may submit, except FFRDCs, UARCs, and Government entities (incl. National Labs), which are not eligible as prime proposers. NAICS: 541714 (biotech R&D). Submissions must comply with U.S. security, export control, and related laws.

What companies and projects are likely to win?

The scoring criteria reward proposals that:

  1. Present a bold, high-impact technical approach. Proposals that merely increment the state of practice are explicitly out-of-scope;

  2. Directly advance DARPA’s national-security mission; and

  3. Show credible cost/schedule realism with clear deliverables and risk-mitigation. Prior experience executing similar efforts and leveraging relevant prior research strengthen competitiveness.

Are there any restrictions I should know about?

  • Abstract is mandatory; DARPA must invite a proposal before it will be reviewed.

  • Compliance areas include CUI handling, cyber (e.g., NIST SP 800-171 assessments), export controls, and human/animal research approvals where applicable.

  • Certain entities/equipment (e.g., Kaspersky, certain telecom/DRONE restrictions, ByteDance apps) are prohibited by clause.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $15,000 Project + a 5% Success Fee.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Read More